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Abstract 
Purpose: To perform a virtual screening for a set of drug-like ligand library against the Staphylococcus 
aureus enoyl acyl carrier protein reductase, saFabI.  
Methods: The virtual screening was conducted based on a previously validated pharmacophore-
constrained docking. Consequently, the top list obtained was filtered using visual inspection where forty 
compounds were selected for experimental testing using disk-diffusion test and broth dilution method. 
The hits obtained were checked for their toxicity against human fibroblasts cell lines.   
Results: Three compounds were active against Staphylococcus aureus and other tested gram-positive 
bacteria. However, no significant inhibitory activity (p < 0.05) was detected against Escherichia coli or 
Candida albicans. The minimum inhibitory concentration (MIC) values for the most active compounds 
were identified using the broth dilution method; all of them exhibited inhibitory activity within micromolar 
range. The docking results showed that the hits obtained exhibited a small size with a nice binding 
mode to saFabI enzyme, forming the important interactions with the key residues. Furthermore, the best 
three hits demonstrated good safety profile as they did not show any significant toxicity against human 
fibroblast cell line.  
Conclusion: Overall, the newly discovered hits can act as a good starting point in the future for the 
development of safe and potent antibacterial agents.   
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Enoyl acyl carrier protein reductases (ENRs) are 
essential enzymes for microorganisms’ survival. 
These enzymes play an important role in the 
elongation process of synthesized fatty acids [1]. 
In the final step of fatty acids elongation pathway, 
ENRs reduce enoyl-thioester to an acyl moiety; 
this reduction process requires a hydride source 
which is provided by a bound NADH or NADPH 
[2].  This particular step in the fatty acid 
elongation pathway is shared amongst many 
organisms, but with significant variation in 
catalysing enzymes’ structure and organisation 
[3]. In bacteria, monofunctional proteins 
catalyses each reaction separately (i.e. FAS II), 
while in human a large multifunctional protein 
(i.e. FAS I) is responsible for all enzymatic 
activities involved in the fatty acids elongation 
pathway. Therefore, bacterial ENRs  are believed 
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to be good specific targets for antibacterial 
agents development, as  they will not affect the 
human FAS I protein [2,3]. 
 
The Staphylococcus aureus FabI (saFabI) is a 
short chain dehydrogenase reductase ENR [3]. 
In general, ENRs have a conserved triad in its 
catalytic sites: Tyrosine, lysine and phenylalanine 
or tyrosine. Whereas the tyrosine residue has a 
direct role in the reduction catalysis by acting as 
a proton donor, lysine’s role is limited to 
stabilizing the binding of the cofactor [4]. The U-
shaped conformation of the fatty acyl substrate is 
guided by the third residue which is located close 
to the nicotinamide ring of NADP [5]. Our 
previous protein-ligand interaction study carried 
on saFabI crystal structures revealed that the 
proton donor Tyr is essential for the binding of 
the co-crystallized inhibitors; a hydrogen bonding 
between them was seen in all examined 
complexes [6]. The bound NADP+ nicotinamide 
ring showed similar importance via making a π-π 
stacking interaction with the corresponding 
aromatic ring of the saFabI inhibitors. In the 
same study, it was revealed that constraining, 
particularly, the first key interaction during 
docking had a positive impact on the enrichment 
of the saFabI virtual screening as well as on the 
docking accuracy of the known saFabI inhibitors 
[6].  
 
The increased resistance of bacteria to existing 
drugs makes the development of new agents a 
crucial step in combating infectious diseases. 
ENRs introduce themselves as potential targets 
for the development of new antibacterial  agents 
[7] and employing the right drug design 
technique against them can eventually turn 
fruitful. In our current study, we employed a 
previously validated virtual screening approach 
[6] to target the saFabI-NADP+ complex with a 
drug-like ligand library. Consequently, the top-
ranked compounds were brought in and tested 
for their antibacterial activity against a panel of 
Gram-negative and Gram-positive bacterial 
strains. The minimum inhibitory concentrations 
were identified for the most active hits. Promising 
hits were then biologically tested against human 





Protein and ligand library preparation 
 
The saFabI crystal structure was obtained from 
the protein data bank (http://www.rcsb.org/), 
PDB: 4ALK [8]. All solvent molecules were 
eliminated prior to protein preparation. The MOE 
3D protonate module [9] was employed to add 
hydrogen atoms to the protein structure and to 
give partial charges to each atom based on the 
MMFF94x force field [10].  
 
A ligand library was obtained from the National 
Cancer Institute/USA (www.cancer.gov). The 
ligands were filtered based on the Veber’s rules 
[11] and the Lipinski’s rule of five [12]. These 
druglikeness filters included: molecular weight ≤ 
500, hydrogen bond donor (HBD) ≤ 5, hydrogen 
bond acceptor (HBA) ≤ 10, logP ≤ 5, polar 
surface area (PSA) ≤ 140 and rotatable bonds ≤ 
10. Ligands were protonated/deprotonated 
based on the Wash module in MOE [9] and were 
then assigned partial charges based on the 
MMFF94x force field [10]. 
 
Virtual screening docking protocol 
 
A docking protocol, that had been previously 
validated by our group [6], was also employed 
here against the saFabI enzyme. Using 
Pharmacophore Elucidation [9], a pharmaco-
phoric feature was created for use in virtual 
screening; the pharmacophoric point was 
assigned based on the NADP+  ribose 2-hydroxyl 
group (denoted as Acc2). Acc2 annotates 
projected locations of potential H-bond donors.  
 
Subsequently, the co-crystallised ligand was 
used to define the saFabI catalytic pocket. Then, 
the prepared druglike ligand library was docked 
into the saFabI enzyme active site using the 
MOE-Dock program [9]. The Pharmacophore 
algorithm was used as a placement method in 
the constrained docking protocol. In the 
Pharmacophore algorithm, the ligand is placed 
using pre-defined pharmacophore and is then 
oriented to take the best fit [9]. Only poses that 
satisfy pharmacophoric features are considered 
for scoring. Affinity dG [9] was used to score and 
rank poses generated from the placement stage; 
the final docking output list included only the top 
ranked pose of each ligand. Affinity dG involves 
several terms for calculating contributions from 
hydrogen bonding, electrostatic and hydrophobic 
interactions.  
 
Top 16000 docked ligands were refined via the 
MMFF94x force field [10] and were consequently 
given binding energies based on the GBVI/WSA 
dG scoring function. Top 2000 ligands of the 
refined list were clustered based on the MACCS 
algorithm [13] and were then visually inspected. 
Ligands from different chemical clusters that 
showed convenient binding modes and nice 
pocket filling were selected for in vitro testing.  
 
As for the reference ligand docking and scoring, 
we found the active conformation of triclosan co-
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crystallized with saFabI in the protein data bank, 
PDB: 4ALL [8]. The whole structure was aligned 
on the protein structure used in this screening so 
that triclosan can get placed accurately inside the 
saFabI catalytic pocket. Afterwards, triclosan was 
refined via the MMFF94x force field and was 





The in vitro antimicrobial activity of all 
compounds against the Gram-positive 
Staphylococcus aureus ATCC25923 was 
determined. Compounds showing significant 
antimicrobial activity against S. aureus were 
selected for further testing against methicillin 
resistant Staphylococcus aureus (MRSA) 
ATCC33591, Bacillus subtilis ATCC6633, Gram-
negative Escherichia coli ATCC25922 and the 
fungus Candida albicans ATCC10231. All strains 
were purchased from Remel Europe (Datford, 
UK). Disk diffusion method was used in the 
preliminary screening as per Clinical Laboratory 
Standards Institute [14], where nutrient agar 
medium (LABM, Lancashire, UK) was used for 
bacteria and Sabouraud dexrose agar medium 
(LABM, Lancashire, UK) was used for fungi. 
Sterile filter paper disks (6mm, sigma, St. Louis, 
MO or Whatman Number 1) were soaked in the 
test compounds dissolved in dimethylsulfoxide, 
(10mM, Sisco Research Lab., Mumbai, India), 
and were allowed to dry at room temperature in 
order to remove any residual solvent. The disks 
were then placed carefully on previously 
inoculated agar plates. The plates were 
incubated at 37 oC for 24 h (bacteria) and 30 oC 
for 48 h (fungi), and the diameter of the growth 
inhibition zones were measured to the nearest 
whole millimeter. 
 
Broth dilution method was used to determine the 
minimum inhibitory concentrations (MIC) for the 
most active compounds NM02 and NM06 against 
S. aureus, MRSA and B. subtilis  as per Clinical 
Laboratory Standards Institute [15] and literature 
[16,17]. Tested compounds were dissolved in 
dimethylsulfoxide where two folds dilutions of the 
solution were prepared and then were diluted in 
culture medium (Nutrient broth, LABM, 
Lancashire, UK) to obtain a final concentration 
range of 0.56 – 143 µg/mL. The 
dimethylsulfoxide final concentration never 
exceeded 1 % v/v. Each test tube was inoculated 
with the microorganism suspensions at 1 X 106 
CFU/mL (colony forming unit/ml) concentrations. 
The MICs were determined after incubation at 37 
oC for 24 h (bacteria). Tubes consisting of growth 
media with 1 % v/v dimethylsulfoxide were used 
as controls. The antibacterial agent; 
chloramphenicol (Sigma, St. Louis, MO); and the 
antifungal agent; ketoconazole (Bio-rad, Marnes-
la-Coquette, France); were used as references. 
All experiments were repeated two times. The 
MIC values were determined as the lowest 
concentrations of compound that completely 
inhibited the visible growth of each strain as 




Fibroblasts were cultivated at 37 °C in 
Dulbecco’s modified Eagles medium (DMEM, 
Biochrom, Berlin, Germany) and 10 % fetal calf 
serum (FCS), (Gibco, Paisley, U.K.) containing 
penicillin/streptomycin (Sigma, St. Louis, MO) 
and amphotericin B (Sigma, St. Louis, MO). Cells 
were plated in 96-well tissue culture plates. Cells 
from passage number 9-15 were used.  For the 
cytotoxicity test, the examined compounds were 
added to the culture medium, at 10 mM 
concentration, and incubated for 24 and 72 h 
incubation periods in an atmosphere of 5 % CO2 
and 95 relative humidity at 37 °C. 
 
In vitro evaluation of the cytotoxicity effects 
associated with the examined compounds was 
performed according to the protocol described in 
the ISO 10993-5 guide [18].  In brief, at the end 
of the exposure period, MTT (3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium 
bromide) assay was carried out as previously 
described [18]. The yellow tetrazolium dye of 
MTT was reduced by metabolically active cells 
into an intracellular purple formazan product. The 
absorbance values of each well were determined 
with a microplate enzyme-linked immuno-assay 
(ELISA) reader equipped with a 570-nm filter. 
Survival rates of the controls were set to 
represent 100 % viability. Untreated cultures 
were used as control groups. Results are 
presented as percentage cell proliferation 
determined as 100- (A of experimental well/A of 
positive control well) X 100. Each experiment 
was repeated 3 times. Statistical analysis was 
performed applying the Student t test using 
SPSS 10.0 statistical software package 
(SPSSFW, SPSS Inc, Chicago, IL. USA) for 





The NCI ligand library was in silico screened 
against the saFabI active site. The virtual 
screening work flow and docking methodology 
are schematically represented in Figure 1. Prior 
docking, the library was filtered to satisfy the 
druglike rules of Lipinski and Veber, decreasing 
the library volume from 273,885 ligands to 
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191,929 ligands. Filtered ligand library was 
docked into the saFabI pocket where a hydrogen 
bonding constraint to the NADP+ ribose was 
applied. The top 16,000 ligands were refined and 
rescored in order to optimize the obtained ligand 
interactions and to remove any existing clashes 
with the surrounding residues. The top 2000 
ligands were clustered and visually inspected 
inside the saFabI binding pocket. Consequently, 
40 compounds from different chemical clusters 
were selected for in vitro testing. 
 
The disk diffusion test was initially used to screen 
the best compounds selected from virtual 
screening against the S. aureus strain. Among 
the 40 compounds tested; NM02, NM06 and 
NM26 showed the highest activity against S. 
aureus whereas the rest of the compounds 
revealed no antibacterial activity (Table 1). The 
three hits obtained from the initial in vitro 
screening were further tested against a wider 
panel of bacterial and fungal strains. 
Consequently, NM02 and NM06 showed varying 
degrees of inhibition against MRSA and B. 
subtilis. Whilst NM06 exhibited weak inhibition 
against MRSA and B. subtilis, NM02 had a 
moderate inhibition activity against the both 
gram-positive strains. In contrast, NM26 
demonstrated no activity against MRSA but had 
slight activity against B. subtilis. None of the 
three hits showed inhibition activity against the 
gram-negative E. coli. On the other hand, NM26 
showed mild inhibition activity against C. albicans 
while NM02 and NM06 possessed no antifungal 
activity. 
 
Compounds NM02 and NM06 were advanced for 
the next stage to identify their MIC values against 
the gram positive strains; results are shown in 
Table 2. Compound NM02 showed moderate 
antibacterial activity against S. aureus, MRSA 
and B. subtilis with a similar MIC value (36 
µg/ml). Comparably, NM06 displayed moderate 
inhibition activity against S. aureus, MRSA and 
B. subtilis with MIC values of 21, 30 and 21 
µg/mL respectively. Both hits had weaker activity 
against S. aureus and B. subtilis compared to the 
positive control (chloramphenicol) which had a 
MIC value of 4 µg/mL against the both gram-
positive strains. Interestingly, NM02 and NM06 
exhibited more than two-fold greater potency 
against MRSA compared to the reference 
compound chloramphenicol (MIC = 74 µg/mL). 
 
 
Figure 1: Virtual screening workflow employed against the saFabI active site using a druglike ligand 
library (A) and the catalytic pocket of the saFabI-NADP+ complex where a ligand is placed inside 
using constrained docking and then refined to minimize clashes and maximize the number of 
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interactions (B). HBD; hydrogen bond donor, HBA, hydrogen bond acceptor, PSA: polar surfer area, 
RB: rotatable bond 
Table 1: Antimicrobial activity of selected compounds tested against different types of bacterial and 
















NM01  - NT NT NT NT 
NM02 + ++ ++ - - 
NM03 – NM05 - NT NT NT NT 
NM06 + + + - - 
NM07 – NM25 - NT NT NT NT 
NM26 + - + - + 
NM27 – NM40 - NT NT NT NT 
Chloramphenicol +++ + +++ +++ NT 
Ketoconazole NT NT NT NT +++ 
Key: - inactive (inhibition zone < 6 mm); slightly active = + (inhibition zone 7–9 mm); moderately 
active = + + (inhibition zone 10-13 mm); highly active = + + + (inhibition zone > 14 mm) (NT= not 
tested) 
 
Table 2: MIC values (µg/mL) of NM02 and NM06 against three bacterial strains along with the MIC 











NM02 36.0 36.0 36.0 
NM06 21.0 30.0 21.0 
Chloramphenicol 4.0 74.0 4.0 
 
Table 3: The GBVI/WSA dG scores of the three active hits obtained from the receptor-based virtual 
screening against saFabI, along with their molecular weight and ligand efficiency 
 





NM02 -6.9 301.3 -0.023 
NM06 -6.4 254.4 -0.025 
NM26 -6.5 224.3 -0.029 
Triclosan -5.6 289.6 -0.019 
 
Table 3 shows the names of the three discovered 
hits along with their predicted binding energies 
and molecular weight. Their binding energies 
were predicted to be favourable, ranging from -
6.9 to -6.4 kcal/mol, scoring even better than the 
reference ligand triclosan (-5.6 kcal/mol). 
Interestingly, all three ligands showed leadlike 
characteristics, especially that they had 
molecular weight ≤ 330 da. As shown in Table 3, 
all three ligands were able to obtain better ligand 
efficiency scores (-0.023 – -0.029 kcal/mol) than 
the reference ligand triclosan (-0.019 kcal/mol) 
as they had lower binding energies and 
comparable or even smaller molecular weight. 
 
On the other hand, the three active compounds 
were assessed for their cytotoxicity activity. After 
incubating the compounds with the fibroblast cell 
line, growth was monitored by MTT assay after 
24 and 72 h. No statistically significant difference 
in cell proliferation was found between wells 
treated with the compounds under examination 
and the control cells (untreated well) after either 





The virtual screening scheme illustrating how the 
drug-like ligand library was prepared, then 
docked into the saFabI active site is shown in 
Figure 1A. During docking, an interaction 
constraint that was previously identified to 
enhance the ENR virtual screening [6] was also 
applied here; to ensure that the key interaction 
with NADP+ ribose will take place (Figure 1B). 
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Constrained docking was previously employed 
against protein tyrosine kinases [19] and 
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Figure 2: Cell proliferation after 24 and 72 h exposure to NM02, NM06 and NM26 
 
in improving their virtual screening enrichment. 
After constrained docking,ligands were refined to 
relieve any existing clash that resulted from the 
constrained docking. Top-ranked ligands were 
clustered then visually inspected to finally select 
40 compounds for experimental testing. 
Interestingly, most of the selected compounds 
had small sizes and contained many of the key 
structural features that are important for saFabI 
binding (e.g. hydrogen bonding with the NADP+ 
ribose, stacking interaction with the NADP+ 
nicotinamide ring and hydrogen bonding with the 
Tyr157 side chain).  
 
Amongst the forty selected ligands that were 
screened experimentally against S. aureus, three 
hits turned to have antimicrobial activity (Table 
1). NM02, NM06 and NM26 had also 
intermediate inhibitory activity against B. subtilis 
but with varied activities against MRSA. 
However, they showed no activity against the 
tested fungal or gram negative bacterial strains. 
NM02 and NM06, in particular, were further 
tested to identify their MIC values which 
indicated that to have micromolar inhibitory 
activity against all tested gram-positive strains 
(Table 2). Interestingly, these two hits had great 
inhibitory activity against the antibiotic resistance 
strain MRSA than the standard antibacterial 
agent, chloramphenicol. The various effects of 
active compounds, against the different types of 
microorganisms tested here, may be caused by 
the cell wall differences amongst the gram-
positive and gram-negative strains. Additionally, 
the shape, size and amino acid sequence of 
ENRs active sites are known to have some 
differences, which hinder the ability of inhibitors 
to act as broad-spectrum antibiotics [3].  
 
It is worth noting that NM26 is a chalcone 
derivative and was previously identified as an 
antibacterial agent. However, in the literature, 
there are controversial results regarding this 
particular compound. Kumar et al [21] found that 
this compound had a strong antibacterial activity 
against E. coli and no inhibition activity against 
the S. aureus strain. In contrast, Al-Mamary et al 
[22] found that this chalcone derivative has a 
strong inhibition activity against S. aureus and 
weak activity against E. coli along with some 
antifungal activity. Our findings appear more 
consistent with the latter finding and it suggests 
out that chalcones may work as antibacterial 
agents via inhibiting the ENR enzymes. 
 
Looking at the binding modes of the three hits, it 
can be observed that NM02 was able to make 
the important hydrogen bonding with the NADP+ 
ribose via its carbonyl oxygen (Figure 3). 
Additionally, it formed multiple van der Waals 
interactions with the surrounding residues (e.g. 
Leu102, Tyr147, Val201) as well as NADP+ 
nicotinamide ring. NM06 was also able to make 
the constrained interaction but this time via its 
imine nitrogen. As shown in Figure 4, NM06 
appears to be nicely filling the active site which 
could further stabilize its binding with the saFabI- 
NADP+ complex. The usual π-π interaction 
shown by different known ENR inhibitors was 
also observed here between the NM06 aromatic 
ring and the NADP+ nicotinamide ring.  
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Figure 3: A. The 2D structure of NM02; B. The best predicted pose of NM02 (orange sticks) inside 
the active site of the ENR-NADP+ complex (ribbon) with the surrounding residues and NADP+ are 
shown as grey and blue sticks, respectively. The picture was generated by MOE. Hydrogen bonding 
is shown as green dotted lines with distance in angstrom  
 
 
Figure 4: A. The 2D structure of NM06; B. The best predicted pose of NM06 (orange sticks) inside 
the active site of the ENR-NADP+ complex (ribbon) with the surrounding residues and NADP+ are 
shown as grey and blue sticks, respectively. The picture was generated by MOE. Hydrogen bonding 
is shown as green dotted lines with distance in angstrom 
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Figure 5: A. The 2D structure of NM26; B. The best predicted pose of NM26 (orange sticks) inside 
the active site of the ENR-NADP+ complex (ribbon) with the surrounding residues and NADP+ are 
shown as grey and blue sticks, respectively. The picture was generated by MOE. Hydrogen bonding 
is shown as green dotted lines with distance in angstrom. 
 
Similar to triclosan, NM26 had its hydroxyl group 
simultaneously interacting with the NADP+ ribose 
and the Tyr157 side chain via hydrogen bonding 
(Figure 5). To sum up, the three hits seem to 
have what is required to interact with the ENR 
active site especially that all of them formed the 
key interaction with the NADP+ ribose hydroxyl. 
Additionally, two of these hits were also able to 
form the common hydrogen bond with Tyr157 or 
the usual π-π stacking interaction with the 
NADP+ nicotinamide ring. 
 
In order to make use of a discovered 
antibacterial hit, its antimicrobial activity should 
be accompanied with no toxicity to the human 
cells. Consequently, a cytotoxicity study for the 
three active compounds was conducted and the 
three hits showed no significant toxicity to the 
tested human cell lines after either 24  or 72 h 
exposure ( 
), indicating a reasonable safety margin of the 
examined compounds on the normal human 
cells. All in all, the three hits discovered here can 
act as good leads to future antibacterial agents; 
especially as they have small structure with the 
important features required to bind with saFabI, 
and more importantly they showed experimental 





A validated structure-based virtual screening 
against the saFabI catalytic pocket has been 
successfully conducted. Forty hits were selected 
for experimental testing, three of which showed 
antibacterial activity, particularly, against gram-
positive strains. Three compounds showed 
convenient docking binding modes, satisfying the 
key interaction with the NADP+ ribose hydroxyl 
group. The MIC values for the best two hits were 
in the micromolar range; both compounds had 
greater activity against MRSA compared to 
chloramphenicol. Interestingly, the two 
discovered compounds showed no toxicity 
towards human cells, indicating a good safety 
profile. The two hits seem to be promising leads 
since they have a good safety margin as well as 
a small molecule size that provides some room 
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